Prescribing Tamoxifen in Patients With Mood Disorders: A Systematic Review of Potential Antimanic Versus Depressive Effects.
Journal
Journal of clinical psychopharmacology
ISSN: 1533-712X
Titre abrégé: J Clin Psychopharmacol
Pays: United States
ID NLM: 8109496
Informations de publication
Date de publication:
Historique:
pubmed:
25
6
2021
medline:
15
12
2021
entrez:
24
6
2021
Statut:
ppublish
Résumé
Tamoxifen is a selective estrogen receptor modulator widely used for treatment and prevention of estrogenic receptor-positive breast cancer. Tamoxifen is an object of growing interest in psychopharmacology as an antimanic drug, because it inhibits the protein kinase C, a molecular target of bipolar disorder. Consistently, the potential depressive effect of tamoxifen has been repeatedly reported. This article systematically reviews studies examining tamoxifen impact on mood, exploring either its potential therapeutic use as antimanic agent or its potential depressive effect. Eight studies explored tamoxifen antimanic properties, all, but one, reported a rapid and efficacious antimanic action. As to the depressive effect, 9 cohort studies emerged among which 4 pointed out an increased risk of depression. Seven case reports described the onset or exacerbation of depressive episodes besides 1 case series study reported a high rate of depressive symptoms. In addition, 1 case report study described a tamoxifen-induced manic episode. The present review highlights tamoxifen treatment as a possible trigger of mood symptoms onset or exacerbation in vulnerable patients. Accordingly, patients with a history of mood disorders may require a close clinical surveillance during tamoxifen use. At the same time, the use of tamoxifen as an antimanic agent in psychiatric settings requires caution, as available evidence came from small-sample studies with short observation time. More studies are needed to define how long-term tamoxifen use may affect the course of bipolar disorder.
Sections du résumé
PURPOSE/BACKGROUND
OBJECTIVE
Tamoxifen is a selective estrogen receptor modulator widely used for treatment and prevention of estrogenic receptor-positive breast cancer. Tamoxifen is an object of growing interest in psychopharmacology as an antimanic drug, because it inhibits the protein kinase C, a molecular target of bipolar disorder. Consistently, the potential depressive effect of tamoxifen has been repeatedly reported.
METHODS/PROCEDURES
METHODS
This article systematically reviews studies examining tamoxifen impact on mood, exploring either its potential therapeutic use as antimanic agent or its potential depressive effect.
FINDINGS
RESULTS
Eight studies explored tamoxifen antimanic properties, all, but one, reported a rapid and efficacious antimanic action. As to the depressive effect, 9 cohort studies emerged among which 4 pointed out an increased risk of depression. Seven case reports described the onset or exacerbation of depressive episodes besides 1 case series study reported a high rate of depressive symptoms. In addition, 1 case report study described a tamoxifen-induced manic episode.
IMPLICATIONS/CONCLUSIONS
CONCLUSIONS
The present review highlights tamoxifen treatment as a possible trigger of mood symptoms onset or exacerbation in vulnerable patients. Accordingly, patients with a history of mood disorders may require a close clinical surveillance during tamoxifen use. At the same time, the use of tamoxifen as an antimanic agent in psychiatric settings requires caution, as available evidence came from small-sample studies with short observation time. More studies are needed to define how long-term tamoxifen use may affect the course of bipolar disorder.
Identifiants
pubmed: 34166298
doi: 10.1097/JCP.0000000000001412
pii: 00004714-900000000-98282
doi:
Substances chimiques
Antimanic Agents
0
Selective Estrogen Receptor Modulators
0
Tamoxifen
094ZI81Y45
Protein Kinase C
EC 2.7.11.13
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
450-460Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Goodman LS, Brunton LL, Chabner B, et al. Goodman & Gilman's pharmacological basis of therapeutics. 12th ed. New York: McGrow-Hill; 2011.
Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13:513–529.
Dhaliwal LK, Suri V, Gupta KR, et al. Tamoxifen: an alternative to clomiphene in women with polycystic ovary syndrome. J Hum Reprod Sci. 2011;4:76–79.
Mannu GS, Sudul M, Bettencourt-Silva JH, et al. Role of tamoxifen in idiopathic gynecomastia: a 10-year prospective cohort study. Breast J. 2018;24:1043–1045.
van der Bilt FE, Hendriksz TR, van der Meijden WA, et al. Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy. Clin Kidney J. 2016;9:184–191.
Few J, Thompson NW, Angelos P, et al. Riedel's thyroiditis: treatment with tamoxifen. Surgery. 1996;120:993–998; discussion 998-9.
Graham CD, Kaza N, Klocke BJ, et al. Tamoxifen induces cytotoxic autophagy in glioblastoma. J Neuropathol Exp Neurol. 2016;75:946–954.
Eugster EA, Rubin SD, Reiter EO, et al., McCune-Albright Study Group. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr. 2003;143:60–66.
Palacios J, Yildiz A, Young AH, et al. Tamoxifen for bipolar disorder:systematic review and meta-analysis. J Psychopharmacol. 2019;33:177–184.
Shagufta, Ahmad I. Tamoxifen a pioneering drug: an update on the therapeutic potential of tamoxifen derivatives. Eur J Med Chem. 2018;143:515–531.
Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.
Tang P, Roldan G, Brasher PM, et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neuro-Oncol. 2006;7:311–316.
Casabona G. Intracellular signal modulation: a pivotal role for protein kinase C. Prog Neuro-Psychopharmacol Biol Psychiatry. 1997;21:407–425.
Wu-Zhang AX, Newton AC. Protein kinase C pharmacology: refining the toolbox. Biochem J. 2013;452:195–209.
Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target?Nat Rev Drug Discov. 2012;11:937–957.
Ferreira JC, Koyanagi T, Palaniyandi SS, et al. Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy. J Mol Cell Cardiol. 2011;51:980–987.
Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106:1319–1313.
Dempsey EC, Cool CD, Littler CM. Lung disease and PKCs. Pharmacol Res. 2007;55:545–559.
Manji HK, Lenox RH. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry. 1999;46:1328–1351.
Huang KP. Role of protein kinase C in cellular regulation. Biofactors. 1990;2:171–178.
Zarate CA, Manji HK. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs. 2009;23:569–582.
Birnbaum SG, Yuan PX, Wang M, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science. 2004;306:882–884.
DiazGranados N, Zarate CA Jr. A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep. 2008;10:510–519.
Gilmer WS. Anticonvulsants in the treatment of mood disorders: assessing current and future roles. Expert Opin Pharmacother. 2001;2:1597–1608.
Hahn CG, Umapathy, Wang HY, et al. Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J Psychiatr Res. 2005;39:355–336.
Talaei A, Pourgholami M, Khatibi-Moghadam H, et al. Tamoxifen: a protein kinase C inhibitor to treat mania: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychopharmacol. 2016;36:272–275.
Armani F, Andersen ML, Galduróz JC. Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology. 2014;231:639–649.
El-Mallakh RS, Elmaadawi AZ, Gao Y, et al. Current and emerging therapies for the management of bipolar disorders. J Cent Nerv Syst Dis. 2011;3:189–197.
Yildiz A, Vieta E, Leucht S, et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36:375–389.
Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30:495–553.
Mikelman S, Mardirossian N, Gnegy ME. Tamoxifen and amphetamine abuse: are there therapeutic possibilities?J Chem Neuroanat. 2017;83-84:50–58.
Mikelman SR, Guptaroy B, Schmitt KC, et al. Tamoxifen directly interacts with the dopamine transporter. J Pharmacol Exp Ther. 2018;367:119–128.
Wharton W, Gleason CE, Olson SR, et al. Neurobiological underpinnings of the estrogen-mood relationship. Curr Psychiatr Rev. 2012;8:247–256.
Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 2001;15:797–817.
Walf AA, Frye CA. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology. 2006;31:1097–1111.
Le J, Thomas N, Gurvich C. Cognition, the menstrual cycle, and premenstrual disorders: a review. Brain Sci. 2020;10:198. doi:10.3390/brainsci/10040198.
doi: 10.3390/brainsci/10040198
Young RC, Moline M, Kleyman F. Hormone replacement therapy and late-life mania. Am J Geriatr Psychiatry. 1997;5:179–181.
Morgan MA, Schulkin J, Pfaff DW. Estrogens and nonreproductive behaviors related to activity and fear. Neurosci Biobehav Rev. 2004;28:55–63.
Watson CS, Alyea RA, Cunningham KA, et al. Estrogens of multiple classes and their role in mental health disease mechanisms. Int J Women's Health. 2010;2:153–166.
Kulkarni J, Riedel A, de Castella AR, et al. Estrogen—a potential treatment for schizophrenia. Schizophr Res. 2001;48:137–144.
Novick AM, Scott AT, Neill Epperson C, et al. Neuropsychiatric effects of tamoxifen: challenges and opportunities. Front Neuroendocrinol. 2020;59:100869.
Azizi-Malekabadi H, Pourganji M, Zabihi H, et al. Tamoxifen antagonizes the effects of ovarian hormones to induce anxiety and depression-like behavior in rats. Arq Neuropsiquiatr. 2015;73:132–139.
Calmarza-Font I, Lagunas N, Garcia-Segura LM. Antidepressive and anxiolytic activity of selective estrogen receptor modulators in ovariectomized mice submitted to chronic unpredictable stress. Behav Brain Res. 2012;227:287–290.
Abrial E, Etievant A, Bétry C, et al. Protein kinase C regulates mood-related behaviors and adult hippocampal cell proliferation in rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;43:40–48.
Thompson DS, Spanier CA, Vogel VG. The relationship between tamoxifen, estrogen, and depressive symptoms. Breast J. 1999;5:375–382.
Lee KC, Ray GT, Hunkeler EM, et al. Tamoxifen treatment and new-onset depression in breast cancer patients. Psychosomatics. 2007;48:205–210.
Chang CH, Chen SJ, Liu CY. Adjuvant treatments of breast cancer increase the risk of depressive disorders: a population-based study. J Affect Disord. 2015;182:44–49.
Morsel AM, Morrens M, Sabbe B. An overview of pharmacotherapy for bipolar I disorder. Expert Opin Pharmacother. 2018;19:203–222.
Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1:351–359.
Taylor DM, Cornelius V, Smith L, et al. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand. 2014;130:452–469.
Ellman R, Thomas BA. Is psychological wellbeing impaired in long-term survivors of breast cancer?J Med Screen. 1995;2:5–9.
Ganz PA, Coscarelli A, Fred C, et al. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat. 1996;38:183–199.
Dow KH, Ferrell BR, Leigh S, et al. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat. 1996;39:261–273.
Anelli TF, Anelli A, Tran KN, et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer. 1994;74:74–77.
Wibowo E, Pollock PA, Hollis N, et al. Tamoxifen in men: a review of adverse events. Andrology. 2016;4:776–788.
Palmer JT, Payne JL. Stabilization of hypomania following initiation of tamoxifen. Am J Psychiatry. 2008;165:650–651.
Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383:1041–1048.
National Institute for Health and Care Excellence, 2013. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Available at https://www.nice.org.uk/guidance/qs39. Accessed November 10, 2020.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
Bebchuk JM, Arfken CL, Dolan-Manji S, et al. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry. 2000;57:95–97.
Kulkarni J, Gurvich C, Gilbert H, et al. Tamoxifen—a potential treatment for women in the manic phase of bipolar affective disorder?Acta Neuropsychiatr. 2006;18:258.
Kulkarni J, Garland KA, Scaffidi A, et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology. 2006;31:543–547.
Zarate CA, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007;9:561–570.
Yildiz A, Guleryuz S, Ankerst DP, et al. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008;65:255–263.
Amrollahi Z, Rezaei F, Salehi B, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord. 2011;129:327–331.
Kulkarni J, Berk M, Wang W, et al. A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. Psychoneuroendocrinology. 2014;43:52–61.
Fallah E, Arman S, Najafi M, et al. Effect of tamoxifen and lithium on treatment of acute mania symptoms in children and adolescents. Iran J Child Neurol. 2016;10:16–25.
Lundberg JC, Theobald D, Ahles TA, et al. Screening to identify and treat tamoxifen-associated side effects. Cancer Pract. 2000;8:211–214.
Lin J, Thompson DS. Case report: tamoxifen-induced depression. Prim Care Update Ob/Gyns. 2001;8:207–208.
Ito M, Baba H, Kawashima R, et al. A case of prolonged depression with tamoxifen. JMAJ. 2006;49:167–172.
Bourque F, Karama S, Looper K, et al. Acute tamoxifen-induced depression and its prevention with venlafaxine. Psychosomatics. 2009;50:162–165.
Kornreich C, Dan B, Vandriette Y. Suicidal risk in a patient receiving tamoxifen treatment for breast cancer. Prim Care Companion J Clin Psychiatry. 2010;12:PCC.09l00828.
De Berardis D, Brucchi M, Serroni N, et al. Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report. Clin Neuropharmacol. 2014;37:31–33.
Arnold BJ, Cumming CE, Lees AW, et al. Tamoxifen in breast cancer: symptom reporting. Breast J. 2001;7:97–100.
Love RR, Cameron L, Connell BL, et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842–1847.
Cathcart CK, Jones SE, Pumroy CS, et al. Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 1993;27:277–281.
Shariff S, Cumming CE, Lees A, et al. Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist. An expected or unexpected effect?Ann N Y Acad Sci. 1995;761:365–368.
Day R; National Surgical Adjuvant Breast and Bowel Projet P-1 study (NSABP-1). Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann N Y Acad Sci. 2001;949:143–150.
Day R, Ganz PA, Costantino JP. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17:2659–2669.
Nystedt M, Berglund G, Bolund C, et al. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer—self-rated physiological effects and symptoms. Acta Oncol. 2000;39:959–968.
Duman B, Kuşman A, Çolak B, et al. Tamoxifen-induced acute mania: a case report. J Oncol Pharm Pract. 2020;26:2025–2027. Epub ahead of print.
Saxena A, Scaini G, Bavaresco DV, et al. Role of protein kinase C in bipolar disorder: a review of the current literature. Mol Neuropsychiatry. 2017;3:108–124.
Tohen M. Clinical trials in bipolar mania: implications in study design and drug development. Arch Gen Psychiatry. 2008;65:252–253.
Kruszewski SP, Paczynski R. Concomitant use of Lorazepam with tamoxifen in bipolar mania clinical trials. Arch Gen Psychiatry. 2009;66:107–8; author reply 108-9.
Fann JR, Thomas-Rich AM, Katon WJ, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30:112–126.
Carvalho AF, Hyphantis T, Sales PM, et al. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. Cancer Treat Rev. 2014;40:349–355.
Meinhard N, Kessing LV, Vinberg M. The role of estrogen in bipolar disorder, a review. Nord J Psychiatry. 2014;68:81–87.
Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. J Affect Disord. 2003;74:67–83.
Pereira M, Martynhak BJ, Baretta IP, et al. Antimanic-like effect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene. Neurosci Lett. 2011;500:95–98.
Sabioni P, Baretta IP, Ninomiya EM, et al. The antimanic-like effect of tamoxifen: behavioural comparison with other PKC-inhibiting and antiestrogenic drugs. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:1927–1931.
Cordeiro C, Simões I, Côrte-Real B, et al. Slim and euthymic tamoxifen and aripiprazole in bipolar disorder. J Clin Psychopharmacol. 2020;40:630–631.